Literature DB >> 19052050

Non-cystic fibrosis bronchiectasis in childhood: longitudinal growth and lung function.

C M Bastardo1, S Sonnappa, S Stanojevic, A Navarro, P Mondejar Lopez, A Jaffe, A Bush.   

Abstract

BACKGROUND: Non-cystic fibrosis (non-CF) bronchiectasis often starts in childhood with a significant impact on adult morbidity. Little is known about disease progression through childhood and the effect on growth and spirometry. This study reviews longitudinal lung function and growth in children with non-CF bronchiectasis.
METHODS: The case notes of patients with non-CF bronchiectasis were reviewed retrospectively. Patients were included if at least three calendar years of lung function data were available. Anthropometric measurements and annual spirometry were analysed over both two and four consecutive years. Changes over time were assessed using Generalised Estimating Equations.
RESULTS: Fifty-nine patients (31 boys) were identified. At baseline the median age was 8.2 years (range 4.8-15.8), the mean (SD) for height, weight and body mass index (BMI) for age z-scores were -0.68 (1.31), -0.19 (1.34) and 0.19 (1.38), respectively. At baseline, the mean (SD) z-score for forced expiratory volume in 1 s (FEV(1)) was -2.61 (1.82). Over 2 years (n = 59), mean FEV(1) and forced vital capacity (FVC) improved by 0.17 (95% CI 0.01 to 0.34, p = 0.039) and 0.21 (95% CI 0.04 to 0.39, p = 0.016) z-scores per annum, respectively. Over 4 years there was improvement in height-for-age z-scores (slope 0.05, 95% CI 0.01 to 0.095, p = 0.01) but no improvement in other anthropometric variables. There was no change in spirometry (FEV(1) slope 0.00, 95% CI -0.09 to 0.09, p = 0.999 and FVC slope 0.09, 95% CI -0.09 to 0.1, p = 0.859).
CONCLUSIONS: Children with non-CF bronchiectasis show adequate growth over time. Lung function stabilises but does not normalise with treatment, underscoring the need for early detection and institution of appropriate therapy.

Entities:  

Mesh:

Year:  2008        PMID: 19052050     DOI: 10.1136/thx.2008.100958

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  19 in total

1.  Culturally Appropriate Outreach Specialist Respiratory Medical Care Improves the Lung Function of Children in Regional and Remote Queensland.

Authors:  Andrew J Collaro; Anne B Chang; Julie M Marchant; Ian B Masters; Leanne T Rodwell; Allan J Takken; Margaret S McElrea
Journal:  Lung       Date:  2020-02-20       Impact factor: 2.584

2.  Chronic suppurative lung disease in adults.

Authors:  Mark L Metersky; Antranik Mangardich
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

3.  Respiratory exacerbations in indigenous children from two countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis.

Authors:  Gregory J Redding; Rosalyn J Singleton; Patricia C Valery; Hayley Williams; Keith Grimwood; Peter S Morris; Paul J Torzillo; Gabrielle B McCallum; Lori Chikoyak; Robert C Holman; Anne B Chang
Journal:  Chest       Date:  2014-09       Impact factor: 9.410

4.  Non-cystic fibrosis bronchiectasis: review and recent advances.

Authors:  Galit Livnat; Lea Bentur
Journal:  F1000 Med Rep       Date:  2009-08-26

5.  Noncystic Fibrosis Bronchiectasis: Evaluation of an Extensive Diagnostic Protocol in Determining Pediatric Lung Disease Etiology.

Authors:  Nike I Beckeringh; Niels W Rutjes; Joost van Schuppen; Taco W Kuijpers
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2019-12-11       Impact factor: 1.349

6.  Children with chronic lung diseases have cognitive dysfunction as assessed by event-related potential (auditory P300) and Stanford-Binet IQ (SB-IV) test.

Authors:  Terez Boshra Kamel; Mahmoud Tarek Abd Elmonaem; Lobna Hamed Khalil; Mona Hamdy Goda; Hossam Sanyelbhaa; Mourad Alfy Ramzy
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-04-13       Impact factor: 2.503

7.  Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial.

Authors:  Anne B Chang; Keith Grimwood; Colin F Robertson; Andrew C Wilson; Peter P van Asperen; Kerry-Ann F O'Grady; Theo P Sloots; Paul J Torzillo; Emily J Bailey; Gabrielle B McCallum; Ian B Masters; Catherine A Byrnes; Mark D Chatfield; Helen M Buntain; Ian M Mackay; Peter S Morris
Journal:  Trials       Date:  2012-08-31       Impact factor: 2.279

8.  Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: protocol for a randomised controlled trial.

Authors:  Kerry-Ann F O'Grady; Keith Grimwood; Allan Cripps; Edward K Mulholland; Peter Morris; Paul J Torzillo; Nicholas Wood; Heidi Smith-Vaughan; Amber Revell; Andrew Wilson; Peter Van Asperen; Peter Richmond; Ruth Thornton; Sheree Rablin; Anne B Chang
Journal:  Trials       Date:  2013-09-05       Impact factor: 2.279

9.  Clinical and research priorities for children and young people with bronchiectasis: an international roadmap.

Authors:  Anne B Chang; Jeanette Boyd; Leanne Bell; Vikas Goyal; I Brent Masters; Zena Powell; Christine Wilson; Angela Zacharasiewicz; Efthymia Alexopoulou; Andrew Bush; James D Chalmers; Rebecca Fortescue; Adam T Hill; Bulent Karadag; Fabio Midulla; Gabrielle B McCallum; Deborah Snijders; Woo-Jung Song; Thomy Tonia; Keith Grimwood; Ahmad Kantar
Journal:  ERJ Open Res       Date:  2021-07-19

10.  Bronchiectasis exacerbation study on azithromycin and amoxycillin-clavulanate for respiratory exacerbations in children (BEST-2): study protocol for a randomized controlled trial.

Authors:  Anne B Chang; Keith Grimwood; Andrew C Wilson; Peter P van Asperen; Catherine A Byrnes; Kerry-Ann F O'Grady; Theo P Sloots; Colin F Robertson; Paul J Torzillo; Gabrielle B McCallum; Ian B Masters; Helen M Buntain; Ian M Mackay; Jacobus Ungerer; Joanne Tuppin; Peter S Morris
Journal:  Trials       Date:  2013-02-20       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.